EPIDEMIOLOGICAL STUDIES, CALCULATION OF INDIRECT COSTS

CLIENT’S BUSINESS OBJECTIVE:
The Client planned to market an innovative drug, for a patient population previously treated suboptimally due to the lack of a dedicated effective treatment. To date, such data was lacking for the Polish patient population.
In order to be well prepared for the launch activities, including reimbursement discussions with the Ministry of Health, the Client needed reliable population data.

CHALLENGES
Due to the broad general patient population, there is a need to identify a dedicated patient population requiring specialised therapy. To date, the lack of precise diagnostics and the lack of available drugs for this group of patients has been a hindrance in identifying this group.

PEX SOLUTION
Extensive epidemiological studies, allowing a detailed description of the population including the subpopulation of interest to the Client
In order to convince decision-makers of the rationale for reimbursement, information on the indirect costs of the patient subpopulation was also collected.

DATA SOURCE
– Patient records,
– retrospective analysis of patient records, 400 descriptions,
– physician interview (online/CAWI), 76 specialists,
– cost survey, 111 patients.

OUTCOME OF THE PROJECT
We estimated the population size, provided medical data on the identified group.
The Client used them in supporting reimbursement efforts and in Advisory Board discussions.
The Client’s drug was reimbursed under the new Drug Programme.
The results of the study formed the basis of a publication in a reputable medical journal.